Recent randomized, placebo-controlled trials have demonstrated that semaglutide, marketed as Ozempic and Wegovy, may slow or even reverse biological aging in humans. One study involving 108 HIV patients showed that those receiving semaglutide exhibited reductions in epigenetic age across multiple methylation clocks after 32 weeks. Another trial with 84 participants found an average biological age reduction of 3.1 years, with some organs appearing nearly 5 years younger. These findings provide the first human evidence supporting semaglutide's potential to impact the aging process beyond its established use for weight loss. Additionally, a 68-week double-blind trial conducted in Japan and South Korea demonstrated that once-daily oral semaglutide (50 mg) led to approximately 14.3% body weight reduction compared to 1.3% with placebo, addressing concerns related to injection aversion. Furthermore, Vivani Medical announced progress on NPM-139, a novel semaglutide implant, following positive preclinical weight loss data and encouraging results from the LIBERATE-1 Phase 1 clinical study of NPM-115.